{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-011579","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.119695+00:00","generated_at":"2026-06-27T00:03:50.464444+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points","bullets":["Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.","FY2021 net loss $12.4M ($1.13/share) vs $5.9M ($1.37/share) in FY2020; R&D expense rose to $7.6M.","RADR AI platform grew from 1.2B to over 18B data points during 2021; target of 25B by end 2022.","LP-300 Phase 2 Harmonic trial for never-smoker NSCLC expected to launch in 2022; LP-184 multiple Phase 1 trials in 2022.","LP-184 received Orphan Drug Designations for pancreatic cancer, GBM, ATRT; Rare Pediatric Disease Designation for ATRT."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-011579","json":"https://secwatch.observer/filing/0001213900-22-011579.json","markdown":"https://secwatch.observer/filing/0001213900-22-011579.md","text":"https://secwatch.observer/filing/0001213900-22-011579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000121390022011579/0001213900-22-011579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000121390022011579/ea156639-8k_lantern.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:03:50.464444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}